DDRE-26. INHIBITION OF PRMT5 SENSITIZES GLIOBLASTOMA MODELS TO TRAMETINIB TREATMENT
Yesh Banasavadi, Balveen Kaur(Augusta University), Ji Young Yoo(The University of Texas MD Anderson Cancer Center), Sarah Rivas(National Institutes of Health), Stuart Walbridge(National Institutes of Health), Yoshihiro Otani(Okayama University), Jean-Paul Bryant(National Institutes of Health), John D. Heiss(National Institutes of Health), Cole T. Lewis(The University of Texas Health Science Center), Ashis Chowdhury(The University of Texas Health Science Center at Houston), Dragan Maric(National Institute of Neurological Disorders and Stroke), Sriya Namagiri(National Institutes of Health), Toshihiko Shimizu(The University of Texas Health Science Center), Tae Jin Lee(Augusta University), Shilpa Thammegowda(Karnataka Veterinary Animal and Fisheries Sciences University), Hannah Sur(National Institutes of Health)
Cited by 0
Related Papers
Microvascular Injury in the Brains of Patients with Covid-19
|New England Journal of Medicine|2020|603
Layer-specific variation of iron content in cerebral cortex as a source of MRI contrast
|Proceedings of the National Academy of Sciences|2010|433
Epigenetic-Mediated Dysfunction of the Bone Morphogenetic Protein Pathway Inhibits Differentiation of Glioblastoma-Initiating Cells
|Cancer Cell|2008|421
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
|Proceedings of the National Academy of Sciences|2006|360